A proportion of patients with drug-resistant tuberculosis (TB) receive ineffective treatment due to misdiagnosis by rapid molecular tests, according to a genomic analysis carried out in southern Mozambique.


Source: CDC/ Antibiotic Resistance Coordination and Strategy Unit

Medical illustration of drug-resistant Mycobacterium tuberculosis bacteria

The study, published in Clinical Infectious Diseases, is co-led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by “la Caixa” Foundation, and the Institute of Biomedicine in Valencia (IBV), from the Spanish National Research Council (CSIC). The results indicate that new molecular tests need to be developed to detect a wider range of mutations that confer resistance to first-line TB drugs.

Mozambique is one of the countries with the highest burden of drug-resistant TB. The World Health Organisation (WHO) recommends use of the Xpert/Ultra molecular test to identify mutations that confer resistance to the first-line drug rifampicin. However, the test does not detect another mutation that also confers resistance to the drug, which was recently identified in Eswatini and South Africa, two countries that share a border with southern Mozambique. In addition, the test does not detect resistance to another first-line drug, isonoazid.

Entire genome

In this study, the teams of Alberto García-Basteiro, researcher at ISGlobal and CISM, and Iñaki Comas, from the IBV, joined forces to evaluate the presence of this and other mutations that confer resistance to anti-TB drugs in the region. To do so, they sequenced the entire genome of the bacterium (M. tuberculosis) from more than 600 patient samples collected during two studies (one in 2018 and the other in 2014) in southern Mozambique. Both resesarchers belong to the CIBER networks of the Health Institute Carlos III.

12.7% of samples (78 out of 612) had one or more mutations conferring resistance to first-line and/or second-line drugs. Ten percent of the strains were resistant to isoniazid and four percent were resistant to rifampicin, the main first-line drugs. The mutation reported in Eswatini and South Africa was found in one strain, but is likely to have arisen locally.

The analysis found two additional mutations conferring rifampicin resistance, which also escape the Xpert/Ultra test. In addition, a high number of isoniazid-resistant cases were detected, which are also missed by the test.

The good news is that no mutations associated with resistance to two new MDR-TB drugs were found in the region, although a recently published study by another group did find increased resistance to bedaquiline.

Increased surveillance needed

“The strain circulating in Eswatini and South Africa does not appear to have spread significantly to the Manhiça region, but we found evidence that strains with other mutations are being transmitted between Mozambique and other countries in the region,” says Comas.

“We observed the circulation of strains resistant to isoniazid but not to rifampicin, and which Xpert/Ultra does not detect,” he adds. The authors therefore stress the need to increase surveillance and broaden the target mutations beyond those detected by the Xpert/Ultra test.

“Our results provide the most recent figures on the prevalence of antimicrobial resistance by Mycobacterium tuberculosis in this region,” says García-Basteiro.

Tuberculosis is the infectious disease that causes the most deaths in the world. In 2022, it was responsible for about 10 million cases and 1.3 million deaths, and about 400,000 people developed TB resistant to one or both first-line drugs. Ending TB is possible, but a collective effort is required.